Role of Nuclear Factor-κB in Breast and Colorectal Cancer

被引:70
|
作者
Zubair, Adeel
Frieri, Marianne [1 ,2 ]
机构
[1] Nassau Univ Med Ctr, Dept Med, Div Allergy Immunol, E Meadow, NY 11554 USA
[2] Nassau Univ Med Ctr, NSLIJ Hlth Care Syst, E Meadow, NY 11554 USA
关键词
Cancer; Nuclear factor-kappa B; NF-kappa B; Breast cancer; Colorectal cancer; Neoplasm; I-kappa B; Carcinoma; TUMOR-NECROSIS-FACTOR; ESTROGEN-RECEPTOR; INDUCED APOPTOSIS; SIGNALING PATHWAYS; TNF-ALPHA; IN-VITRO; ACTIVATION; EXPRESSION; INHIBITOR; PHOSPHORYLATION;
D O I
10.1007/s11882-012-0300-5
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
The purpose of this review article is to highlight articles and new research regarding the link between NF-AB and several cancers. This review presents the most up-to-date NF-AB research and how it links this important transcription factor with hematology and oncology. It was written by conducting a thorough search of Pubmed as well as several journals such as Cancer, Nature, Science, Cell and those of one of the authors. The articles relating to the link between NF-AB and cancer were used to write this review. The results of this study clarified that there is a critical link between NF-AB and cancer. NF-AB has often been implicated in a variety of different diseases and it plays a variety of roles in cell survival, differentiation, and proliferation of cells. In cancer, NF-AB plays a pivotal role by facilitating oncogenesis as well as metastasis. A thorough understanding of NF-AB and its role in cancer can lead to future studies and drug development which could provide a novel option in the treatment of this disease.
引用
收藏
页码:44 / 49
页数:6
相关论文
共 50 条
  • [41] Nuclear factor-κB:: A holy grail in cancer prevention and therapy
    Aggarwal, Bharat B.
    Sethi, Gautam
    Nair, Asha
    Ichikawa, Haruyo
    CURRENT SIGNAL TRANSDUCTION THERAPY, 2006, 1 (01) : 25 - 52
  • [42] Nuclear transcription factor-κB as a target for cancer drug development
    Garg, A
    Aggarwal, BB
    LEUKEMIA, 2002, 16 (06) : 1053 - 1068
  • [43] Nuclear transcription factor-κB as a target for cancer drug development
    A Garg
    BB Aggarwal
    Leukemia, 2002, 16 (6) : 1053 - 1068
  • [44] Endogenous inhibitors of nuclear factor-κB, an opportunity for cancer control
    Chen, F
    CANCER RESEARCH, 2004, 64 (22) : 8135 - 8138
  • [45] Epithelial migration:: A novel role of nuclear factor-κB (NF-κB)
    Strauch, ED
    Wang, JY
    Li, L
    Jaladanki, RN
    Vann, JA
    Bass, BL
    GASTROENTEROLOGY, 2001, 120 (05) : A139 - A139
  • [46] Increased expression of RelA/nuclear factor-κB protein correlates with colorectal tumorigenesis
    Yu, HG
    Yu, LL
    Yang, YN
    Luo, HS
    Yu, JP
    Meier, JJ
    Schrader, H
    Bastian, A
    Schmidt, WE
    Schmitz, F
    ONCOLOGY, 2003, 65 (01) : 37 - 45
  • [47] Nuclear factor-ĸB plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells
    Kumiko Oida
    Akira Matsuda
    Kyungsook Jung
    Yan Xia
    Hyosun Jang
    Yosuke Amagai
    Ginnae Ahn
    Sho Nishikawa
    Saori Ishizaka
    Erika Jensen-Jarolim
    Hiroshi Matsuda
    Akane Tanaka
    Scientific Reports, 4
  • [48] Nuclear factor-κB plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells
    Oida, Kumiko
    Matsuda, Akira
    Jung, Kyungsook
    Xia, Yan
    Jang, Hyosun
    Amagai, Yosuke
    Ahn, Ginnae
    Nishikawa, Sho
    Ishizaka, Saori
    Jensen-Jarolim, Erika
    Matsuda, Hiroshi
    Tanaka, Akane
    SCIENTIFIC REPORTS, 2014, 4 : 1 - 8
  • [49] Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-κB inactivation
    Kim, Dae-Seok
    Park, Sung-Soo
    Nam, Byung-Ho
    Kim, In-Hoo
    Kim, Soo-Youl
    CANCER RESEARCH, 2006, 66 (22) : 10936 - 10943
  • [50] Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-κB activity
    Cicek, M
    Fukuyama, R
    Welch, DR
    Sizemore, N
    Casey, G
    CANCER RESEARCH, 2005, 65 (09) : 3586 - 3595